CLINICAL EVALUATION OF PRIMIDONE (MYSOLINE), NEW ANTICONVULSANT DRUG
- 6 March 1954
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 154 (10) , 827-829
- https://doi.org/10.1001/jama.1954.02940440025007
Abstract
An appreciable number of patients with seizures are not helped by the standard anticonvulsants. There is, therefore, a constant search for new agents that will benefit this group. A new synthetic compound, primidone (Mysoline), has been made available to a number of investigators, and the results of four separate clinical trials had been reported at the time of writing.1Handley and Stewart1afound this drug to be effective in 80% of 40 patients with grand mal seizures. In Butler's series1bof 58 patients with all types of seizures, there was improvement in 50% of patients with grand mal attacks. Smith and McNaughton1cwere able to evaluate the results of primidone therapy in 61 patients and found that 35% were improved. Bonkalo and Arthurs1dreported on the use of primidone in the treatment of epileptic and nonepileptic psychiatric patients. They noted a reduction in the seizureKeywords
This publication has 0 references indexed in Scilit: